39.48
39.48 (0%)
As of Apr 17, 2025
Cytokinetics Inc [CYTK]
Source:
Company Overview
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | (650) 624-3000 |
| Industry | manufacturing |
| CEO | Robert I. Blum Robert Blum |
| Website | www.cytokinetics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $18.5 |
| Operating Profit | $-536.2 |
| Net Income | $-589.5 |
| Net Cash | $-18.2 |
Profit Ratios
| Gross Margin | $18.5 |
| Operating Margin | -2,902.7 |
| Profit as % of Revenues | -3.1% |
| Profit as % of Assets | -53% |
| Profit as % of Stockholder Equity | 435.5% |
Management Effectiveness
| Return on Equity | 435.5% |
| Return on Assets | -42.1% |
| Turnover Ratio | 1.7% |
| EBITA | $-536.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,401.7 |
| Total Liabilities | $1,537 |
| Operating Cash Flow | $-395.9 |
| Investing Cash Flow | $-553.1 |
| Financing Cash Flow | $930.6 |
